ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Sionna Therapeutics (SION)
Sionna Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$3.87▲ +4.88%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
39%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Sionna Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Sionna Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Sionna Therapeutics a 39% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $2.47 and $4.64; in 9 out of 10, between $1.41 and $8.12. Estimated annual volatility is 195%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $222M
- 52-week high
- $54.97
- 52-week low
- $3.55
- Revenue (12 months)
- $0.0M
- Return on equity
- -32.3%
- Free cash flow (12 months)
- $-45.4M
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for SION right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks SION has traded between $3.55 and $54.97. Today it is 93.0% below that high and 9% above its low.
Its beta is 0.00: it tends to move less than the market.
About the company
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cystic fibrosis.
Want to see everything about Sionna Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Sionna Therapeutics do?
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cystic fibrosis.
What is the chance SION goes up next month?
39%: somewhat worse than a coin flip. In half of the simulated outcomes, SION ends the month between $2.47 and $4.64.
How big is Sionna Therapeutics and what is its P/E ratio?
Sionna Therapeutics's market capitalization is $222M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is SION?
ATLAS estimates annual volatility at 195%. In a typical month, half of the outcomes end between $2.47 and $4.64.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer